Betatalassemia maior
Incertezas e riscos das transfusões
Seropositivity of hepatitis C, hepatitis B and HIV in chronically transfused β-thalassaemia major patients. (abre nova janela)
Fonte: J Coll Physicians Surg Pak 2012;22(9):610-1.
Indexado: PubMed 22980623
DOI: 09.2012/JCPSP.610611
https://www.ncbi.nlm.nih.gov/pubmed/22980623 (abre nova janela)
Clinical outcome of frequent exposure to Torque Teno virus (TTV) through blood transfusion in thalassemia patients with or without hepatitis C virus (HCV) infection. (abre nova janela)
Fonte: J Med Virol 2008;80(2):365-71.
Indexado: PubMed 18098140
DOI: 10.1002/jmv.21070
https://www.ncbi.nlm.nih.gov/pubmed/18098140 (abre nova janela)
Prevalence of alloimmunisation in patients with beta thalassaemia major. (abre nova janela)
Fonte: Blood Transfus 2012;10(3):396-7.
Indexado: PubMed 22395351
DOI: 10.2450/2012.0072-11
https://www.ncbi.nlm.nih.gov/pubmed/22395351 (abre nova janela)
Marseillevirus prevalence in multitransfused patients suggests blood transmission. (abre nova janela)
Fonte: J Clin Virol 2013;58(4):722-5.
Indexado: PubMed 24183312
DOI: 10.1016/j.jcv.2013.10.001
https://www.ncbi.nlm.nih.gov/pubmed/24183312 (abre nova janela)
Thalassemia Major in Adults: Short Stature, Hyperpigmentation, Inadequate Chelation, and Transfusion-Transmitted Infections are Key Features. (abre nova janela)
Fonte: N Am J Med Sci 2012;4(3):141-4.
Indexado: PubMed 22454828
DOI: 10.4103/1947-2714.93886
https://www.ncbi.nlm.nih.gov/pubmed/22454828 (abre nova janela)